Notes and Corrections: In the video, Adam mentions that Numinus doesn’t have a footprint in North America. This was misstated. What he meant to say is that Numinus didn’t have a footprint in the USA until after acquiring Novamind.
A lot has happened over the past week. In the above video, Psychedelic Invest’s Adam Tubero gets into some of the highlights coming out of the psychedelic sector within the past week.
Elon Musk Continues to Talk Psychedelics
In the second time over the past few weeks, Elon is created waves with his tweets. This time around, he replies directly to the CEO of Cybin with a promising note about the future of psychedelic medicine.
No matter how you want to look at it, or what you think of Elon, his opinions can create movements. So it’s important we stay on top of moments like these and measure the outcomes on an ongoing basis.
ARK Continues to Deep Dive the Sector
Cathie Wood is back at it again. It seems we’re getting closer to some major moves from her firm, ARK Invest, after some teaser comments were made public about their intentions with the psychedelics market.
We can’t wait to see what happens next.
Numinus Finalizes the Acquisition of Novamind
This acquisition makes Numinus the largest biotech company that’s focusing on psychedelic clinics.
What Do You Think?
What are your thoughts on all of this recent news? Leave your comments over on the Psychedelic Invest YouTube channel.